6-chloro-N-isobutyl-3-nitropyridin-2-amine | 1005349-59-6

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 6-chloro-N-isobutyl-3-nitropyridin-2-amine
• 英文别名: 6-chloro-N-(2-methylpropyl)-3-nitropyridin-2-amine
• CAS: 1005349-59-6
• 化学式: C₉H₁₂ClN₃O₂
• mdl: MFCD11206187
• 分子量: 229.666
• InChiKey: CEURVZPCUQOWOW-UHFFFAOYSA-N

物化性质

• 沸点：
  354.4±42.0 °C(Predicted)
• 密度：
  1.306±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  70.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-chloro-N-isobutyl-3-nitropyridin-2-amine 在 platinum on carbon 、 氢气 、 次磷酸 作用下， 以 甲苯 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 以97.6%的产率得到6-chloro-N2-isobutylpyridine-2,3-diamine
  参考文献：
  名称：

  Preparation of 2-Aminopyridoimidazoles and 2-Aminobenzimidazoles via Phosphorus Oxychloride-Mediated Cyclization of Aminoureas

  摘要：

  The novel preparation of 2-aminopyridoimidazoles and 2-aminobenzimidazoles via the cyclization of (2-aminopyridin-3-yl)urea and (2-aminophenyl)urea substrates in the presence of phosphorus oxychloride is described. This methodology is demonstrated for a range of urea substrates with aminoimidazole products obtained in good yields and with excellent levels of purity.

  DOI：

  10.1021/jo500360k
• 作为产物：
  描述：

  2,6-二氯-3-硝基吡啶 、 异丁胺 在 sodium carbonate 作用下， 以 异丙醇 为溶剂， 生成 6-chloro-N-isobutyl-3-nitropyridin-2-amine
  参考文献：
  名称：

  Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors

  摘要：

  A new class of potent and selective PDE5 inhibitors is disclosed. Guided by X-ray crystallographic data, optimization of an HTS lead led to the discovery of a series of 2-aryl, (N8)-alkyl substituted-6-aminosubstituted pyrido[3,2b]pyrazinones which show potent inhibition of the PDE5 enzyme. Synthetic details and some structure-activity relationships are also presented. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.06.012

文献信息

• [EN] COMBINATION THERAPY FOR OVARIAN CANCER<br/>[FR] POLYTHÉRAPIE UTILISÉE POUR LE CANCER DE L'OVAIRE
  申请人：LILLY CO ELI

  公开号：WO2013070460A1

  公开（公告）日：2013-05-16

  The present invention provides a method of treating ovarian cancer in a mammal in need of such treatment comprising administering an effective amount of a combination of gemcitabine, cisplatin or carboplatin, and 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine.

  本发明提供了一种治疗需要此类治疗的哺乳动物卵巢癌的方法，包括给予一种有效量的吉西他滨、顺铂或卡铂以及5-[2-叔丁基-5-(4-氟苯基)-1H-咪唑-4-基]-3-(2,2-二甲基丙基)-3H-咪唑并[4,5-b]吡啶-2-基胺的组合物。
• Combination Therapy for Ovarian Cancer
  申请人：Eli Lilly and Company

  公开号：US20140302174A1

  公开（公告）日：2014-10-09

  The present invention provides a method of treating ovarian cancer in a mammal in need of such treatment comprising administering an effective amount of a combination of gemcitabine, cisplatin or carboplatin, and 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine.

  本发明提供了一种治疗哺乳动物卵巢癌的方法，包括向需要此类治疗的哺乳动物投予有效量的吉西他滨、顺铂或卡铂和5-[2-叔丁基-5-(4-氟苯基)-1H-咪唑-4-基]-3-(2,2-二甲基丙基)-3H-咪唑[4,5-b]吡啶-2-胺的组合物。
• Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38α MAP kinase inhibitors with excellent in vivo antiinflammatory properties
  作者：Mary Mader、Alfonso de Dios、Chuan Shih、Rosanne Bonjouklian、Tiechao Li、Wesley White、Beatriz López de Uralde、Concepción Sánchez-Martinez、Miriam del Prado、Carlos Jaramillo、Eugenio de Diego、Luisa M. Martín Cabrejas、Carmen Dominguez、Carlos Montero、Timothy Shepherd、Robert Dally、John E. Toth、Arindam Chatterjee、Sehila Pleite、Jaime Blanco-Urgoiti、Leticia Perez、Mario Barberis、María José Lorite、Enrique Jambrina、C. Richard Nevill、Paul A. Lee、Richard C. Schultz、Jeffrey A. Wolos、Li C. Li、Robert M. Campbell、Bryan D. Anderson

  DOI：10.1016/j.bmcl.2007.10.106

  日期：2008.1

  Herein we report investigations into the p38 alpha MAP kinase activity of trisubstituted imidazoles that led to the identification of compounds possessing highly potent in vivo activity. The SAR of a novel series of imidazopyridines is demonstrated as well, resulting in compounds possessing cellular potency and enhanced in vivo activity in the rat collagen-induced arthritis model of chronic inflammation. (C) 2007 Elsevier Ltd. All rights reserved.
• COMBINATION THERAPY FOR OVARIAN CANCER
  申请人：Eli Lilly and Company

  公开号：EP2780011A1

  公开（公告）日：2014-09-24